Kymera Therapeutics has leadership transitions

 

Kymera Therapeutics Inc. has appointed the company’s co-founder and chief scientific officer, Nello Mainolfi, Ph.D., as president. The company’s former president and CEO, Laurent Audoly, Ph.D., has decided to pursue new entrepreneurial opportunities. Additionally, health care financial services veteran Bruce Jacobs joins as chief financial officer to direct financial operations and investor relations.

“On behalf of the entire board, I would like to thank Laurent for his significant contributions in the formative stages of Kymera’s development and progress,” says Bruce Booth, DPhil, co-founder and chairman of the Kymera board and partner at Atlas Venture. “Under Laurent’s leadership, the company advanced key corporate and research opportunities and cultivated an impressive team of drug hunters.”

As president, Mainolfi directs all company operation and continues to serve as chief scientific, overseeing Kymera’s research and development efforts. An executive search for the CEO role is currently under way.

“Laurent’s vision and dedication have positioned the company on a successful trajectory,” Mainolfi says. “I am excited to welcome Bruce Jacobs to Kymera and look forward to working with our leadership team, board of directors, and partners to build on our tremendous progress in the field and deliver on our commitment to discover truly groundbreaking protein degrader drugs for patients.”

Jacobs joins Kymera with more than 25 years of experience in health care financial services, investment banking, and equity research. Jacobs previously was managing partner for Westfield Capital Management, a Boston-based equity   investment firm. In addition to his core portfolio management responsibilities, he served on the firm’s management committee and as the Health Care Team Lead. Jacobs was also a director with Alex Brown & Sons/Deutsche Bank and part of the health care investment banking group and the equity research team. He graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned a master of business administration from the Harvard Business School, and is a chartered financial analyst.

“I’m excited to join the Kymera team in their inspired mission to unlock the promise of targeted protein degradation and help facilitate the drug discovery process to develop novel therapies for patients,” Jacobs says.